The Ebola outbreak in the Democratic Republic of the Congo (DRC) requires an estimated $1.4 billion in funding to be brought under control, a significant increase from earlier projections. This dire need was highlighted during a press conference by Jean Kaseya, MD, MPH, Director-General of the Africa Centres for Disease Control and Prevention.
“Without this $1.4 billion and without resolving the humanitarian challenges, we will not contain this outbreak,” Dr. Kaseya stated. While approximately $910 million has been pledged, only a fraction, 13%, has been disbursed. The situation in Ituri province is deteriorating, with healthcare workers facing considerable difficulties accessing displacement camps where the virus may be spreading undetected. Six weeks into the declared outbreak, response efforts are still struggling to keep pace. An international research group’s new dashboard indicates the outbreak has reached 1,118 cases with 291 fatalities.
In parallel, the White House is seeking congressional approval for an additional $1.4 billion to combat the Ebola crisis. The Office of Management and Budget’s supplemental request includes $550 million for Ebola prevention and detection within the DRC and $800 million for humanitarian aid. This humanitarian funding is earmarked for various initiatives, including the construction of an Ebola facility in Kenya, despite recent halts to such projects by Kenyan authorities. OMB Director Russell Vought emphasized in a letter to Congress that these funds aim to prevent the virus from spreading beyond the DRC and Uganda to other vulnerable nations and to safeguard against its arrival in the United States.
Meanwhile, UNICEF and Gavi, the Vaccine Alliance, have initiated a Request for Expression of Interest (EOI) to gauge the capacity of vaccine manufacturers for developing a vaccine against the Bundibugyo Ebolavirus. Currently, no vaccine exists for this specific species. This initiative complements Gavi’s recent $40 million commitment to expedite vaccine access. According to a UNICEF press release, the EOI will guide how these funds can best support manufacturing scale-up and ensure prompt availability of doses should a vaccine become viable.
Reference